New Treatment With Human Atrial Natriuretic Peptide for Postoperative Myonephropathic Metabolic Syndrome Akira Sezai, MD, PhD, Mitsumasa Hata, MD, PhD, Tesuya Niino, MD, PhD, Isamu Yoshitake, MD, PhD, Satoshi Unosawa, MD, PhD, Hisaki Umezawa, MD, PhD, Kazutomo Minami, MD, PhD The Annals of Thoracic Surgery Volume 88, Issue 4, Pages 1333-1335 (October 2009) DOI: 10.1016/j.athoracsur.2009.02.075 Copyright © 2009 The Society of Thoracic Surgeons Terms and Conditions
Fig 1 Preoperative computed tomography scan shows acute aortic dissection (arrow, right iliac artery). The Annals of Thoracic Surgery 2009 88, 1333-1335DOI: (10.1016/j.athoracsur.2009.02.075) Copyright © 2009 The Society of Thoracic Surgeons Terms and Conditions
Fig 2 Urine volume is shown after the (top panel) AAD repair and (bottom panel) dosage of human atrial natriuretic peptide (hANP). The Annals of Thoracic Surgery 2009 88, 1333-1335DOI: (10.1016/j.athoracsur.2009.02.075) Copyright © 2009 The Society of Thoracic Surgeons Terms and Conditions
Fig 3 Changes in concentrations of (top panel) creatine kinase and (bottom panel) creatinine. (ICU = intensive care unit). The Annals of Thoracic Surgery 2009 88, 1333-1335DOI: (10.1016/j.athoracsur.2009.02.075) Copyright © 2009 The Society of Thoracic Surgeons Terms and Conditions